AIMS: Retinoids are involved in cell growth, differentiation, and carcinogenesis. Their effects depend on cytosolic transport and binding to nuclear receptors. CRBP1 encodes a protein involved in this process. Because altered CRBP1 expression and promoter hypermethylation occur in several tumours, these changes were investigated in prostate tumorigenesis. METHODS: The CRBP1 promoter was assessed by methylation specific polymerase chain reaction on tissue samples from 36 radical prostatectomy specimens (paired normal tissue, adenocarcinoma, and high grade prostatic intraepithelial neoplasia (HGPIN)), 32 benign prostatic hyperplasias (BPHs), and 13 normal prostate tissue samples from cystoprostatectomies. Methylation of DNA extracted from microdissected tissue was examined blindly. CRBP1 expression was assessed by immunohistochemistry on formalin fixed, paraffin wax embedded tissue. RESULTS: Loss of CRBP1 expression was seen in 15 of 36 adenocarcinomas and 18 of 36 HGPINs. Fifteen adenocarcinomas and nine HGPINs showed overexpression, whereas the remainder showed normal expression. BPH displayed normal expression. No significant associations were found between CRBP1 expression and Gleason score or stage. CRBP1 promoter hypermethylation was found in 17 of 36 adenocarcinomas, three of 35 HGPINs, one of 36 normal prostate tissues from the same patients, none of 32 BPHs, and none of 13 normal prostate tissues from cystoprostatectomies. Loss of expression and hypermethylation of CRBP1 were not significantly associated. CONCLUSIONS: Altered CRBP1 expression and hypermethylation are common in prostate carcinoma, although CRBP1 hypermethylation is not an early event in tumorigenesis. Moreover, both adenocarcinoma and HGPIN show frequent CRBP1 overexpression. The molecular mechanisms underlying altered CRBP1 expression in prostate cancer deserve further study.
AIMS: Retinoids are involved in cell growth, differentiation, and carcinogenesis. Their effects depend on cytosolic transport and binding to nuclear receptors. CRBP1 encodes a protein involved in this process. Because altered CRBP1 expression and promoter hypermethylation occur in several tumours, these changes were investigated in prostate tumorigenesis. METHODS: The CRBP1 promoter was assessed by methylation specific polymerase chain reaction on tissue samples from 36 radical prostatectomy specimens (paired normal tissue, adenocarcinoma, and high grade prostatic intraepithelial neoplasia (HGPIN)), 32 benign prostatic hyperplasias (BPHs), and 13 normal prostate tissue samples from cystoprostatectomies. Methylation of DNA extracted from microdissected tissue was examined blindly. CRBP1 expression was assessed by immunohistochemistry on formalin fixed, paraffin wax embedded tissue. RESULTS: Loss of CRBP1 expression was seen in 15 of 36 adenocarcinomas and 18 of 36 HGPINs. Fifteen adenocarcinomas and nine HGPINs showed overexpression, whereas the remainder showed normal expression. BPH displayed normal expression. No significant associations were found between CRBP1 expression and Gleason score or stage. CRBP1 promoter hypermethylation was found in 17 of 36 adenocarcinomas, three of 35 HGPINs, one of 36 normal prostate tissues from the same patients, none of 32 BPHs, and none of 13 normal prostate tissues from cystoprostatectomies. Loss of expression and hypermethylation of CRBP1 were not significantly associated. CONCLUSIONS: Altered CRBP1 expression and hypermethylation are common in prostate carcinoma, although CRBP1 hypermethylation is not an early event in tumorigenesis. Moreover, both adenocarcinoma and HGPIN show frequent CRBP1 overexpression. The molecular mechanisms underlying altered CRBP1 expression in prostate cancer deserve further study.
Authors: S Vogel; C L Mendelsohn; J R Mertz; R Piantedosi; C Waldburger; M E Gottesman; W S Blaner Journal: J Biol Chem Date: 2001-01-12 Impact factor: 5.157
Authors: C Folli; V Calderone; S Ottonello; A Bolchi; G Zanotti; M Stoppini; R Berni Journal: Proc Natl Acad Sci U S A Date: 2001-03-27 Impact factor: 11.205
Authors: C Jerónimo; H Usadel; R Henrique; J Oliveira; C Lopes; W G Nelson; D Sidransky Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: Q Yang; I Mori; L Shan; M Nakamura; Y Nakamura; H Utsunomiya; G Yoshimura; T Suzuma; T Tamaki; T Umemura; T Sakurai; K Kakudo Journal: Am J Pathol Date: 2001-01 Impact factor: 4.307
Authors: Carmen Jerónimo; Graça Varzim; Rui Henrique; Jorge Oliveira; Maria José Bento; Cristina Silva; Carlos Lopes; David Sidransky Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-05 Impact factor: 4.254
Authors: Gergely Bánfi; Ivett Teleki; Péter Nyirády; Attila Keszthelyi; Imre Romics; Attila Fintha; Tibor Krenács; Béla Szende Journal: Int Urol Nephrol Date: 2015-05-08 Impact factor: 2.370
Authors: Jeannette M Schenk; Elio Riboli; Nilanjan Chatterjee; Michael F Leitzmann; Jiyoung Ahn; Demetrius Albanes; Douglas J Reding; Yinghui Wang; Marlin D Friesen; Richard B Hayes; Ulrike Peters Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-31 Impact factor: 4.254